CSF levels of tau, β-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging

被引:209
作者
Sjögren, M
Minthon, L
Davidsson, P
Granérus, AK
Clarberg, A
Vanderstichele, H
Vanmechelen, E
Wallin, A
Blennow, K
机构
[1] Univ Gothenburg, Sahlgrens Univ Hosp, Inst Clin Neurosci, SE-43180 Molndal, Sweden
[2] Lund Univ, Dept Community Med, S-22100 Lund, Sweden
[3] Malmo Univ Hosp, Neuropsychiat Clin, Malmo, Sweden
[4] Univ Hlth Sci, Dept Geriatr, Linkoping, Sweden
[5] Innogenetics, Ghent, Belgium
关键词
Alzheimer's disease; frontotemporal dementia; vascular dementia; subcortical; while matter; Parkinson's disease; cerebrospinal fluid; GAP-43; tau; beta-amyloid; biochemical marker;
D O I
10.1007/s007020070079
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Cerebrospinal fluid (CSF) levels of tau, beta-amyloid(1-42) and growth-associated protein 43 (GAP-43) were studied in patients with frontotemporal dementia (FTD; n = 17), Alzheimer's disease (AD; n = 60), subcortical white-matter dementia (SWD; n = 24), Parkinson's disease (PD; n = 23) and dysthymia (n = 19) and in age-matched controls (n = 32). CSF-tau was significantly increased only in AD, and CSF-beta-amyloid(1-42) was significantly decreased in AD and SWD as compared to controls, and in AD compared to FTD. CSF-GAP-43 was significantly decreased only in PD. The GAP-43/tau ratio was decreased in all the patient groups except the dysthymia group compared to controls. A positive correlation was found between CSF-GAP-43 and CSF-tau in all groups. The results suggest normal levels of CSF-tau and CSF-beta-amyloid(1-42) in FTD, which will aid in the clinical separation of FTD from AD. In SWD, decreased levels of CSF-beta-amyloid(1-42) suggest concomitant involvement of vascular and amyloid protein mechanisms.
引用
收藏
页码:563 / 579
页数:17
相关论文
共 62 条
  • [1] Altman DG, 1991, Practical Statistics for Medical Research, DOI DOI 10.1002/SIM.4780101015
  • [2] Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109
  • [3] Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease:: a community based follow up study
    Andreasen, N
    Vanmechelen, E
    Van de Voorde, A
    Davidsson, P
    Hesse, C
    Tarvonen, S
    Räihä, I
    Sourander, L
    Winblad, B
    Blennow, K
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1998, 64 (03) : 298 - 305
  • [4] Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease -: Differences between early- and late-onset Alzheimer disease and stability during the course of disease
    Andreasen, N
    Hesse, C
    Davidsson, P
    Minthon, L
    Wallin, A
    Winblad, B
    Vanderstichele, H
    Vanmechelen, E
    Blennow, K
    [J]. ARCHIVES OF NEUROLOGY, 1999, 56 (06) : 673 - 680
  • [5] Prevalence and incidence of clinically diagnosed memory impairments in a geographically defined general population in Sweden -: The Pitea Dementia Project
    Andreasen, N
    Blennow, K
    Sjodin, C
    Winblad, B
    Svärdsudd, K
    [J]. NEUROEPIDEMIOLOGY, 1999, 18 (03) : 144 - 155
  • [6] No increase in cerebrospinal fluid tau protein levels in patients with vascular dementia
    Arai, H
    Satoh-Nakagawa, T
    Higuchi, M
    Morikawa, Y
    Miura, M
    Kawakami, H
    Seki, H
    Takase, S
    Sasaki, H
    [J]. NEUROSCIENCE LETTERS, 1998, 256 (03) : 174 - 176
  • [7] TAU IN CEREBROSPINAL-FLUID - A POTENTIAL DIAGNOSTIC MARKER IN ALZHEIMERS-DISEASE
    ARAI, H
    TERAJIMA, M
    MIURA, L
    HIGUCHI, S
    MURAMATSU, T
    MACHIDA, N
    SEIKI, H
    TAKASE, S
    CLARK, CM
    LEE, VMY
    TROJANOWSKI, JQ
    SASAKI, H
    [J]. ANNALS OF NEUROLOGY, 1995, 38 (04) : 649 - 652
  • [8] Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology
    Arai, H
    Morikawa, Y
    Higuchi, M
    Matsui, T
    Clark, CM
    Miura, M
    Machida, N
    Lee, VMY
    Trojanowski, JQ
    Sasaki, H
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 236 (02) : 262 - 264
  • [9] PRIMARY STRUCTURE AND TRANSCRIPTIONAL REGULATION OF GAP-43, A PROTEIN ASSOCIATED WITH NERVE GROWTH
    BASI, GS
    JACOBSON, RD
    VIRAG, I
    SCHILLING, J
    SKENE, JHP
    [J]. CELL, 1987, 49 (06) : 785 - 791
  • [10] PROTEIN ANALYSES IN CEREBROSPINAL-FLUID .1. INFLUENCE OF CONCENTRATION GRADIENTS FOR PROTEINS ON CEREBROSPINAL-FLUID SERUM-ALBUMIN RATIO
    BLENNOW, K
    FREDMAN, P
    WALLIN, A
    GOTTFRIES, CG
    LANGSTROM, G
    SVENNERHOLM, L
    [J]. EUROPEAN NEUROLOGY, 1993, 33 (02) : 126 - 128